⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Large Cap · Disruption threat: MEDIUM
Veeva is incrementally embedding AI into its life sciences cloud suite—spanning CRM, data, and vault applications—positioning AI as a product differentiator for pharma and biotech customers. The 10-K signals continued R&D investment in AI features but no material revenue stream yet attributable solely to AI, keeping the score stable.
Veeva Systems (VEEV) provides cloud-based software solutions exclusively for the life sciences industry, serving pharmaceutical, biotech, and medical device companies across CRM, regulatory, and clinical data applications. With an overall AI score of 62/100, Veeva occupies a moderate position — meaningfully engaged with AI but not yet a leader in monetizing it. Product AI Integration (65/100) and R&D AI Investment (60/100) are the clearest strengths, reflecting tangible deployments such as AI-assisted clinical data analysis, intelligent document processing within Vault, and AI-driven CRM recommendations tailored to life sciences sales teams. Automated regulatory submission workflows represent another practical application. However, Revenue from AI (25/100) and AI Infrastructure (45/100) remain notable drags, confirming that AI is currently enhancing existing products rather than generating a distinct, measurable revenue contribution. A medium disruption threat reflects Veeva's defensible position within a highly regulated, relationship-driven vertical. Life sciences customers face significant switching costs and compliance barriers, limiting the speed at which AI-native competitors could displace entrenched workflows. The key opportunity lies in converting incremental AI features into premium-priced offerings as pharma customers increasingly demand workflow automation. The key risk is commoditization if larger enterprise platforms replicate Veeva's AI capabilities at scale before a distinct revenue stream materializes.
Full interactive analysis at RankVis.io